The arginine metabolome in acute lymphoblastic leukemia can be targeted by the pegylated-recombinant arginase I BCT-100.

Autor: De Santo C; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Booth S; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Vardon A; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Cousins A; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom., Tubb V; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom., Perry T; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom., Noyvert B; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom., Beggs A; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom., Ng M; Department of Anatomic Pathology, The Chinese University of Hong Kong, Hong Kong., Halsey C; Institute of Cancer Sciences, Wolfson Wohl Cancer Research Centre, College of Medical, Veterinary and Life Sciences, University of Glasgow, United Kingdom., Kearns P; Institute of Cancer and Genomic Sciences, University of Birmingham, Birmingham, United Kingdom., Cheng P; Bio-Cancer Treatment International Ltd, Hong Kong., Mussai F; Institute of Immunology and Immunotherapy, University of Birmingham, Birmingham, United Kingdom.
Jazyk: angličtina
Zdroj: International journal of cancer [Int J Cancer] 2018 Apr 01; Vol. 142 (7), pp. 1490-1502. Date of Electronic Publication: 2017 Dec 26.
DOI: 10.1002/ijc.31170
Abstrakt: Arginine is a semi-essential amino acid that plays a key role in cell survival and proliferation in normal and malignant cells. BCT-100, a pegylated (PEG) recombinant human arginase, can deplete arginine and starve malignant cells of the amino acid. Acute lymphoblastic leukemia (ALL) is the most common cancer of childhood, yet for patients with high risk or relapsed disease prognosis remains poor. We show that BCT-100 is cytotoxic to ALL blasts from patients in vitro by necrosis, and is synergistic in combination with dexamethasone. Against ALL xenografts, BCT-100 leads to a reduction in ALL engraftment and a prolongation of survival. ALL blasts express the arginine transporter CAT-1, yet the majority of blasts are arginine auxotrophic due to deficiency in either argininosuccinate synthase (ASS) or ornithine transcarbamylase (OTC). Although endogenous upregulation or retroviral transduced increases in ASS or OTC may promote ALL survival under moderately low arginine conditions, expression of these enzymes cannot prevent BCT-100 cytotoxicity at arginine depleting doses. RNA-sequencing of ALL blasts and supporting stromal cells treated with BCT-100 identifies a number of candidate pathways which are altered in the presence of arginine depletion. Therefore, BCT-100 provides a new clinically relevant therapeutic approach to target arginine metabolism in ALL.
(© 2017 The Authors International Journal of Cancer published by John Wiley & Sons Ltd on behalf of UICC.)
Databáze: MEDLINE
Externí odkaz: